<DOC>
	<DOCNO>NCT02485249</DOCNO>
	<brief_summary>To evaluate safety efficacy ocular iontophoresis dexamethasone phosphate ophthalmic solution , EGP-437 , use EyeGate® II Drug Delivery System ( EGDS ) patient macular edema ( ME )</brief_summary>
	<brief_title>Open-label , Multli-center , Phase 1b/2a Clinical Trial Designed Evaluate Safety Efficacy Iontophoretic Dexamethasone Phosphate Ophthalmic Solution Patients With Macular Edema</brief_title>
	<detailed_description>This Phase 1b/2a , exploratory , open-label study , 20 eligible ME patient enrol 5 clinical site U.S. Twenty eye 20 patient enrol mean one eye treat study treatment patient present Visit 1 bilateral ME . In situation eye patient eligible study , eye shorter duration ME study eye.9 The investigator designate study eye eligible eye diagnose ME time . Potential patient interested participate study provide informed consent form ( ICF ) prior screen . Patient eligibility assess Visit 1 ( Day 0 ) , baseline visit , spectral SD-OCT measurement IOP , addition review patient 's medical ophthalmic history recent concomitant medication history . Study Treatment administer Day 0 , Day 4 , Day 9 ( Visits 1 , 2 , 3 ) . Subjects schedule return clinic post-treatment assessment Visits 4 5 ( Day 14 Day 21 Day 28 ) .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>1 . Age 18 90 year 2 . Have diagnosis ME secondary one follow diagnosed condition : 1 . Central branch retinal vein occlusion ( CRVO BRVO ) mean CST ≥ 300µm SDOCT image take baseline visit ( Day 0 ) 2 . Diabetic macular edema ( DME ) mean CST ≥ 300µm SDOCT image take baseline visit ( Day 0 ) 3 . Cystoid macular edema ( CME ) secondary undergone previous PPV mean CST ≥ 300µm SDOCT image take baseline visit ( Day 0 ) history previous positive response steroid treatment 3 . Receive , understand , sign copy ICF 4 . Be able return study visit willing comply study relate instruction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Iontophoresis</keyword>
	<keyword>Macular Edema</keyword>
	<keyword>Ophthalmology</keyword>
</DOC>